Program
ceralasertib
Also written as “Ceralasertib”, “Ceralasertib 160 mg OD + olaparib continuous 300 mg BD (28-day cycle).” and “[14C] AZD6738”.
Its studies are mostly in Carcinoma, Non-Small-Cell Lung · Triple Negative Breast Neoplasms · Neoplasms · Leukemia, Lymphocytic, Chronic, B-Cell · Melanoma, led by AstraZeneca.
Drug pageCeralasertib: every studyAll 46 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| AstraZeneca | 167 open or running | phase 3since Jul 6, 2022 | Sep 30, 2013 | none ahead |
Also a collaborator on its studies: Parexel.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
Before these, 2 studies since Sep 30, 2013.
- Jan 13, 2017Phase 1 study in Squamous Cell Carcinoma of Head and NeckNCT03022409 · 21 enrolled · United States, France, Taiwan
- Sep 22, 2017Phase 2 study in Carcinoma, Non-Small-Cell LungNCT03334617 · 528 enrolled · United States, Austria, Canada and more
- Oct 16, 2017Phase 2 study in Triple Negative Breast NeoplasmsNCT03330847 · 273 enrolled · United States, Belgium, Canada and more
- Oct 30, 2017Phase 1 study in Leukemia, Lymphocytic, Chronic, B-CellNCT03328273 · 12 enrolled · Poland, United Kingdom
- Apr 24, 2018Phase 1 study in Lymphoma, Non-HodgkinNCT03527147 · 30 enrolled · United States, United Kingdom
- Jun 9, 2018Named ceralasertibINNProposed as its International Nonproprietary Name in WHO's List 119
- Jan 21, 2020Phase 2 study in Ovarian NeoplasmsNCT04239014 · United States, Canada, Italy and more
- Sep 8, 2020Phase 2 study in Hereditary Sensory and Autonomic NeuropathiesNCT04564027 · 54 enrolled · United States, France, Spain
- Sep 22, 2021Phase 2 study in MelanomaNCT05061134 · 194 enrolled · United States, Australia, Belgium and more
- May 18, 2022Phase 1 study in Advanced Solid MalignanciesNCT05469919 · 12 enrolled · Japan
- Jul 6, 2022Phase 3 study in Carcinoma, Non-Small-Cell LungNCT05450692 · 594 enrolled · United States, Argentina, Australia and more
- Aug 23, 2022Phase 1 study in Advanced Solid TumoursNCT05514132 · 14 enrolled · China
- Jun 12, 2023Phase 2 study in Carcinoma, Non-Small-Cell LungNCT05941897 · 39 enrolled · Russia
- Nov 4, 2024Phase 1 study in NeoplasmsNCT06754761 · 2 enrolled · United Kingdom
- Apr 14, 2025Phase 1 study in Advanced Solid TumoursNCT06929260 · 1 enrolled · United Kingdom
TargetBeta
“An orally available morpholino-pyrimidine-based inhibitor of ataxia telangiectasia and rad3 related (ATR) kinase, ”NCIt, by rule
“Serine-protein kinase ATR inhibitor”ChEMBL 37, by rule
Other programs on ATR
Studies
All 16 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06929260Advanced Solid Tumours · United Kingdom | 1 | Terminated | Oct 15, 2025 | 1 |
| NCT06754761Neoplasms · United Kingdom | 1 | Terminated | Oct 21, 2025 | 2 |
| NCT05941897Carcinoma, Non-Small-Cell Lung · Russia | 2 | Active, not recruiting | Jul 29, 2024 | 39 |
| NCT05514132Advanced Solid Tumours · China | 1 | Active, not recruiting | Oct 20, 2023 | 14 |
| NCT05450692Carcinoma, Non-Small-Cell Lung · United States, Argentina, Australia and more | 3 | Active, not recruiting | Oct 6, 2025 | 594 |
| NCT05469919Advanced Solid Malignancies · Japan | 1 | Completed | Aug 17, 2023 | 12 |
| NCT05061134Melanoma · United States, Australia, Belgium and more | 2 | Active, not recruiting | Apr 12, 2024 | 194 |
| NCT04564027Hereditary Sensory and Autonomic Neuropathies · United States, France, Spain | 2 | Completed | Feb 18, 2025 | 54 |
| NCT04239014Ovarian Neoplasms · United States, Canada, Italy and more | 2 | Withdrawn | Jan 25, 2021 | 0 |
| NCT03527147Lymphoma, Non-Hodgkin · United States, United Kingdom | 1 | Completed | Mar 31, 2021 | 30 |
| NCT03328273Leukemia, Lymphocytic, Chronic, B-Cell · Poland, United Kingdom | 1 | Active, not recruiting | Sep 7, 2021 | 12 |
| NCT03330847Triple Negative Breast Neoplasms · United States, Belgium, Canada and more | 2 | Active, not recruiting | Nov 13, 2020 | 273 |
| NCT03334617Carcinoma, Non-Small-Cell Lung · United States, Austria, Canada and more | 2 | Active, not recruiting | Sep 13, 2024 | 528 |
| NCT03022409Squamous Cell Carcinoma of Head and Neck · United States, France, Taiwan | 1 | Completed | Jan 20, 2021 | 21 |
| NCT02937818Platinum Refractory Extensive-Stage Small Cell Lung Carcinoma · Germany, Hungary, Poland and more | 2 | Completed | Jun 22, 2020 | 72 |
| NCT01955668Leukemia, B-Cell · United States | 1 | Completed | Dec 2013 | 2 |
How it is read
Names in the registry
- “Ceralasertib”, 11 entries
- “Ceralasertib 160 mg OD + olaparib continuous 300 mg BD (28-day cycle).”, 1 entry
- “[14C] AZD6738”, 1 entry
- “AZD6738 / ceralasertib”, 1 entry
- “AZD6738 and olaparib”, 1 entry
Codes read as this program: AZD6738.
Conditions, from the studies’ own filings
- Carcinoma, Non-Small-Cell Lung, 3 studies
- Triple Negative Breast Neoplasms, 1 study
- Neoplasms, 1 study
- Leukemia, Lymphocytic, Chronic, B-Cell, 1 study
- Melanoma, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.